SIGA Stock Recent News

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc. (NASDAQ:SIGA) ("SIGA" or the "Company") SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

NEW YORK , Sept. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company") SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company.

In the closing of the recent trading day, Siga Technologies Inc. (SIGA) stood at $8.43, denoting no change from the preceding trading day.

So-called “bull traps” often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today.

SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients failed to meet its primary endpoint but showed safety. SIGA's reliance on US government contracts, especially for TPOXX, introduces substantial revenue concentration risk.

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary analysis of the PALM 007 (Tecovirimat for Treatment of Monkeypox Virus) clinical trial (NCT05559099). NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo (DRC) with monkeypox (mpox), who were administered SIGA's tecovirimat, a highly targeted antiviral treatment, versus placebo. All patients in this study were hospitalized for the entire duration of treatment. This study was not a registration study conducted under an U.S. FDA Investigational New Drug Application.

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Operator Welcome to SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 1, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

Siga Technologies Inc. (SIGA) reachead $9.72 at the closing of the latest trading day, reflecting a +0.83% change compared to its last close.